Future mRNA Vaccine Applications Highlighted
The New York Post recently published an article discussing future applications of mRNA, including vaccinations against tuberculosis, malaria, high cholesterol, HIV, and more.
4D Molecular Therapeutics (4DMT) Acquires Rights to Penn Medicine Invented Technology from Aevitas Therapeutics
Penn spinout Aevitas Therapeutics recently executed an asset purchase agreement with California-based biotechnology company 4D Molecular Therapeutics (4DMT).
Adult Schizophrenia Drug Wins FDA Approval
Teva Pharmaceuticals and MedinCell recently received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone).
Penn Medicine Magazine Showcases Penn’s Drug Research and Development and Commercial Partnerships
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co
Technology to help Newborns in the NICU wins 2023 President’s Innovation Prize
Penn President Liz Magill awarded the 2023 President’s Innovation Prize toGabriella Daltoso, Sophie Ishiwari, Gabriela Cano, Caroline Amanda Magro, and Tifara Eliana Boyce for their project, Sonura.
Bruce Levine Speaks on the Future of CAR-T Therapies
Levine explained that there are currently six approved CAR-T therapies and he estimates that between 25,000 and 30,000 patients have been treated with those therapies globally.
Ligand-tethered Lipid Nanoparticles for Targeted RNA Delivery to Treat Liver Fibrosis
the Mitchell Lab has developed a new class of anisimide-functionalized lipids that enables targeted delivery of lipid nanoparticles (LNPs) to activated fibroblasts in the liver.
Fake
This technology is an intracerebral drug delivery system that consists of three flexible, retractable microcannulas housed within a single central catheter.
Mitchell Lab’s Targeted Prenatal Therapy for Mothers and Their Babies Addresses Gap in Health Equity
The researchers’ successful trials in mice show that the technology may potentially lead to promising treatment options for humans with pre-eclampsia.